This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Algeta: The prostate cancer radio-pharmaceutical Alpharadin was submitted to FDA in December so Algeta is still waiting to hear on filing acceptance and priority review. Even though Alpharadin is much easier to use than previous radio-pharmaceutical disappointments like Bexxar and Zevalin and despite stellar survival data, Wall Street investors remain generally suspect about Algeta's commercial prospects. The company needs a speedy FDA approval and a strong launch (hopefully in the back half of 2013) to reverse the skepticism.

Opko Health (OPK): I'm finally going to dig into Opko, to figure out if there's anything more substantive to the company beyond the celebrity status of Chairman and CEO Phil Frost.

Wednesday, Jan. 9 (Feeling really tired by now)

Spectrum Pharmaceuticals (SPPI): What, if anything, can CEO Raj Shrotriya say to scare the shorts, who have nested comfortably in this stock for a year? For starters, Shrotriya should offer more details from the phase III study of belinostat in peripheral T-cell lymphoma. Disclosure to date has been woefully inadequate. Shrotriya will also surely be peppered with questions about the future growth of Fusilev in the face of leucovorin supply slowly coming back on line.

Nektar Therapeutics (NKTR): Like many investors, I'm still waiting for Nektar and its partner AstraZeneca to tell us what really happened with the phase III study of opioid constipation drug naloxogel. How much bio-statistical jujitsu was necessary to turn a failed study into one with "positive" results?

NPS Pharmaceuticals (NPSP): You're really going to price Gattex at $295,000 per year?

Isis Pharmaceuticals (ISIS): When European regulators rejected Isis' HoFH drug Kynamro, supporters defended, claiming the company's real value lies in its deep antisense drug pipeline. Okay, show us what you got.

Ziopharm Oncology (ZIOP - Get Report): The only thing that matters are data from the phase III study of palifosfamide in soft-tissue sarcoma. Results expected before the end of the first quarter.

Amicus Therapeutics (FOLD): What caused the failure of the Amigal study in Fabry disease? We may not get the answer until data are presented at a medical meeting in February, but Amicus management will be needled with questions during the breakout session.

Arena Pharmaceuticals (ARNA): The commercial launch of its weight-loss pill Belviq is imminent, making Arena the best short of 2013 or a soon-to-be blockbuster. [You <a href="">know my stance</a>.]

Idenix Pharmaceuticals (IDIX): 2012 started off bright for Idenix with shares soaring on optimism about its hepatitis C drug portfolio and speculation about a takeout. That all went to crap in August when FDA placed two Idenix drugs on clinical hold -- casualties of the cardiovascular toxicities that killed Bristol-Myers Squibb's BMS-094.

Those two Idenix drugs, IDX-184 and IDX-368, remain on FDA clinical hold, although the company hopes to hear good news from the agency in the first quarter. After that, Idenix needs to play a serious game of catch-up drug development if it wants to remain a viable Hep C player.

Exact Sciences (EXAS): Top-line results from the pivotal validation study of Cologuard, the company's non-invasive colon cancer screening test, will be released in March.

Sarepta Therapeutics (SRPT): Expect incremental updates from CEO Chris Garabedian about timelines for eteplirsen in 2013.

Thursday, Jan. 10 (I'll be on a plane flying home but in case you're still paying attention...)

MannKind (MNKD): Round two of Afrezza phase III data coming. Al Mann still can't find a partner or enough investors to care about inhalable insulin.

Questcor Pharmaceuticals (QCOR): Is there anything Questcor management can do to stem the criticisms about its Acthar pricing and marketing practices?

Keryx Pharmaceuticals (KERX): Investors are still waiting for results from the long-term safety study of the phosphate binder Zerenex. Even if approved, Keryx needs to figure out how to sell a premium-priced drug in a generic and highly competitive dialysis market.

Vical (VICL): Waiting to hear if Allovectin melanoma data will be pushed back again -- this time to 2016.

Geron (GERN): Condolences.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
ZIOP $5.10 0.00%
AMRN $1.38 0.00%
CELG $97.89 0.00%
GILD $85.14 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs